SCHEMBL4355643

SCHEMBL4355643

CCCCCCOC(=O)Nc1ccc(O)cc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
HPGD P15428 2/20 0.48
KDM4E B2RXH2 2/20 0.48
EPHX1 P07099 1/20 0.47
ESR1 P03372 1/20 0.47
AKR1C4 P17516 1/20 0.47
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
AKR1C1 Q04828 1/20 0.47
LMNA P02545 3/20 0.46
TSHR P16473 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 1/20 0.45
HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27887821 0.81 PLK1 (0.52) SMN1; SMN2CYP1A2CYP2C19
SCHEMBL30729910 0.81 SMN1; SMN2 (0.54) SMN1; SMN2CYP1A2CYP2C19ALDH1A1L3MBTL1
SCHEMBL8624857 0.78 HTT (0.52) SMN1; SMN2ALDH1A1HPGDKDM4EEPHX1
SCHEMBL8624344 0.78 HTT (0.52) SMN1; SMN2ALDH1A1HPGDKDM4EEPHX1
SCHEMBL8388607 0.78 HTT (0.52) SMN1; SMN2ALDH1A1HPGDKDM4EEPHX1
SCHEMBL8391457 0.78 HTT (0.52) SMN1; SMN2ALDH1A1HPGDKDM4EEPHX1
SCHEMBL4839353 0.78 PLK1 (0.67) SMN1; SMN2CYP1A2CYP2C19ALDH1A1L3MBTL1
SCHEMBL4744334 0.78 HPGD (0.73) SMN1; SMN2CYP1A2CYP2C19ALDH1A1L3MBTL1
SCHEMBL8756355 0.78 EP300 (0.62) SMN1; SMN2ALDH1A1L3MBTL1HPGDKDM4E
SCHEMBL20302856 0.78 RAB9A (0.64) SMN1; SMN2CYP1A2CYP2C19ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885CYP1A2 215/4885CYP2C19 976/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885CYP1A2 147/4885CYP2C19 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.